Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 9/20 | 0.67 |
| ▸ | GAK | O14976 | 2/20 | 0.47 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.45 |
| ▸ | NEK2 | P51955 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5464535 | 0.93 | NOS1 (0.77) | NOS1GAKMAP4K1NEK2ACHE | |
| SCHEMBL5481513 | 0.87 | NOS1 (0.65) | NOS1GAKMAP4K1NEK2ACHE | |
| SCHEMBL5456864 | 0.85 | NOS1 (0.78) | NOS1GAKMAP4K1NEK2ACHE | |
| SCHEMBL5510661 | 0.81 | NOS1 (0.83) | NOS1GAKMAP4K1NEK2PDE4A | |
| SCHEMBL5513542 | 0.81 | NOS1 (0.98) | NOS1GAKMAP4K1NEK2PDE4A | |
| SCHEMBL4460917 | 0.81 | NOS1 (0.81) | NOS1GAKNEK2 | |
| Water SCHEMBL6499440 | 0.81 | NOS1 (0.81) | NOS1GAKMAP4K1NEK2PDE4A | |
| SCHEMBL5509568 | 0.80 | NOS1 (1.00) | NOS1GAKMAP4K1NEK2PDE4A | |
| Water SCHEMBL6481921 | 0.80 | NOS1 (0.80) | NOS1GAKNEK2 | |
| SCHEMBL5459346 | 0.79 | NOS1 (0.64) | NOS1GAKMAP4K1NEK2PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318456-A1 | SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318456-A1 | SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | HAVCR2, TYMP, HCCS | NOS1 3411/4885GAK 1647/4885MAP4K1 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.